The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $77.80

Today's change0.00 0.00%
Updated June 30 4:00 PM EDT. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $77.80

Today's change0.00 0.00%
Updated June 30 4:00 PM EDT. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc closed at (U.S.)$77.80.

Over the last five days, shares have lost 6.99% and are down 25.74% for the last year to date. This security has underperformed the S&P 500 by 44.85% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $77.80
  • High--
  • Low--
  • Bid / Ask(U.S.) $75.90 / (U.S.) $81.00
  • YTD % change-25.74%
  • Volume0
  • Average volume (10-day)2,096,400
  • Average volume (1-month)1,466,407
  • Average volume (3-month)1,576,798
  • 52-week range(U.S.) $62.12 to (U.S.) $151.75
  • Beta1.06
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.18
Updated June 30 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-20.50%

Although this company's net profit margin is negative, it is above the industry average and implies that Biomarin Pharmaceutical Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.20%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue237228209251
Total other revenue--------
Total revenue237228209251
Gross profit194185172211
Total cost of revenue43433740
Total operating expense318127291315
Selling / general / administrative9811493100
Research & development159176159158
Depreciation / amortization8811
Interest expense (income), net operating--------
Unusual expense (income)0-1710--
Other operating expenses, total3-44114
Operating income-81101-82-64
Interest income (expense), net non-operating-10-9-9-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-8993-90-83
Income after tax-8569-91-82
Income tax, total-4240-1
Net income-8569-91-82
Total adjustments to net income--------
Net income before extra. items-8569-91-82
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-8569-91-82
Inc. avail. to common incl. extra. items-8569-91-82
Diluted net income-8569-91-82
Dilution adjustment--------
Diluted weighted average shares162161161160
Diluted EPS excluding extraordinary itemsvalue per share-0.530.43-0.57-0.51
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.53-0.26-0.57-0.51